Tomáš Zima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomáš Zima has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Marta Kalousová
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
99 shared publications - Barbora Stastna
Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
34 shared publications - Jana Soukupova
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
34 shared publications - Marketa Janatova
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
34 shared publications - Petra Kleiblova
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
34 shared publications - Zdenek Kleibl
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia
34 shared publications
Latest Publications
- 19 October 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Biogenic amines as neuroendocrine tumor markers: limitations and future perspectives
Biogenic amines and their metabolites are central biochemical markers in the diagnosis and management of catecholamine-producing neuroendocrine tumors, including pheochromocytoma, paraganglioma, and neuroblastoma. Despite decades of clinical use, their wider implementation remains limited by substantial physiological variability, pre-analytical influences, and methodological heterogeneity across laboratories. The transition from colorimetric and immunoassay-based techniques to liquid chromatography–tandem mass spectrometry has markedly improved analytical sensitivity and specificity. The multiplexing capacity of modern mass spectrometric platforms has enabled comprehensive quantification of biogenic amine profiles, thereby increasing diagnostic sensitivity in tumor subtypes in which individual biomarkers exhibit limited performance. Increasing attention has been given to dopamine derived metabolites, especially 3-methoxytyramine, which is associated with MYCN-related tumor biology and unfavorable clinical outcomes in neuroblastoma and selected paraganglioma subtypes. However, the analytical complexity of mass spectrometric approaches, together with the absence of full metrological traceability, continues to limit inter-laboratory comparability. In this review, we critically evaluate the analytical evolution of biogenic amine testing, the principal pre-analytical and methodological determinants that influence the interpretation of results, and current efforts to improve harmonization. Particular emphasis is placed on the potential of biogenic amines as prognostic biomarkers and on the need to integrate expanded biogenic amine profiling into clinically robust, comparable diagnostic approaches that may advance precision oncology.
- 19 October 2026
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
Biogenic amines as neuroendocrine tumor markers: limitations and future perspectives
Biogenic amines and their metabolites are central biochemical markers in the diagnosis and management of catecholamine-producing neuroendocrine tumors, including pheochromocytoma, paraganglioma, and neuroblastoma. Despite decades of clinical use, their wider implementation remains limited by substantial physiological variability, pre-analytical influences, and methodological heterogeneity across laboratories. The transition from colorimetric and immunoassay-based techniques to liquid chromatography–tandem mass spectrometry has markedly improved analytical sensitivity and specificity. The multiplexing capacity of modern mass spectrometric platforms has enabled comprehensive quantification of biogenic amine profiles, thereby increasing diagnostic sensitivity in tumor subtypes in which individual biomarkers exhibit limited performance. Increasing attention has been given to dopamine derived metabolites, especially 3-methoxytyramine, which is associated with MYCN-related tumor biology and unfavorable clinical outcomes in neuroblastoma and selected paraganglioma subtypes. However, the analytical complexity of mass spectrometric approaches, together with the absence of full metrological traceability, continues to limit inter-laboratory comparability. In this review, we critically evaluate the analytical evolution of biogenic amine testing, the principal pre-analytical and methodological determinants that influence the interpretation of results, and current efforts to improve harmonization. Particular emphasis is placed on the potential of biogenic amines as prognostic biomarkers and on the need to integrate expanded biogenic amine profiling into clinically robust, comparable diagnostic approaches that may advance precision oncology.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Characteristics of 12 case-control datasets from the ENIGMA consortium partners.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Characteristics of 12 case-control datasets from the ENIGMA consortium partners.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Detail description of the functional categorization of analyzed CHEK2 missense variants.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Detail description of the functional categorization of analyzed CHEK2 missense variants.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
List of all analyzed CHEK2 variants with results of KAP1/CHK2 kinase and localization assays and the results from recent previously published functional analyses of the CHEK2 VUS.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
List of all analyzed CHEK2 variants with results of KAP1/CHK2 kinase and localization assays and the results from recent previously published functional analyses of the CHEK2 VUS.
- Open Access
- 19 October 2025
- Published by Charles University in Prague, Karolinum Press in Envigogika
- Vol. 20 (2)
Dělat věci, které mají smysl
K devadesátým narozeninám profesora Bedřicha Moldana
- 19 October 2025
- Published by Charles University in Prague, Karolinum Press in Envigogika
- Vol. 20 (2)
Open AccessDělat věci, které mají smysl
K devadesátým narozeninám profesora Bedřicha Moldana
- 27 June 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (12) , 2371-2376
The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference
Laboratory investigations are important in the clinical management and the study of chronic kidney disease–mineral and bone disorder (CKD-MBD)- including CKD-associated osteoporosis. Parathyroid hormone (PTH) is the major hormone in the regulation of bone and calcium balance but is significantly affected in advanced CKD. Knowledge of PTH concentration is important in the assessment of osteoporosis including CKD-associated osteoporosis; however, measurement of PTH in the laboratory is bedevilled by interferences and inter-method differences compounded by lack of standardisation of commonly used immunoassays. Vitamin D is important for bone health and its deficiency contributes to the development of osteoporosis. Vitamin D metabolism is impaired in advanced CKD, augmenting the effects of its deficiency on bone health. Lack of consensus on optimal serum 25-hydroxyvitamin D (25-(OH)D) concentrations for bone health, including in the various CKD stages, is compounded by lack of analytical specificity of immunoassays. Liquid chromatography tandem mass spectrometry (LC-MS/MS) assays would help overcome these issues. Ionised calcium measurement is recommended for assessment of serum calcium, especially in CKD. Fibroblast growth factor 23 (FGF23) is important in the homeostasis of phosphate that accumulates in CKD, though this marker is not yet utilized in clinical context. Calculated maximal tubular reabsorption of phosphate normalized to glomerular filtration rate (TmP/GFR) may help in assessment of phosphate homeostasis. Bone specific alkaline phosphatase (BALP) and tartrate-resistant acid phosphatase isoform 5b (TRACP5b), the reference markers of bone formation and resorption for CKD-associated osteoporosis, have been shown to reflect bone turnover by histomorphometry in patients with advanced CKD.
- 27 June 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (12) , 2371-2376
The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference
Laboratory investigations are important in the clinical management and the study of chronic kidney disease–mineral and bone disorder (CKD-MBD)- including CKD-associated osteoporosis. Parathyroid hormone (PTH) is the major hormone in the regulation of bone and calcium balance but is significantly affected in advanced CKD. Knowledge of PTH concentration is important in the assessment of osteoporosis including CKD-associated osteoporosis; however, measurement of PTH in the laboratory is bedevilled by interferences and inter-method differences compounded by lack of standardisation of commonly used immunoassays. Vitamin D is important for bone health and its deficiency contributes to the development of osteoporosis. Vitamin D metabolism is impaired in advanced CKD, augmenting the effects of its deficiency on bone health. Lack of consensus on optimal serum 25-hydroxyvitamin D (25-(OH)D) concentrations for bone health, including in the various CKD stages, is compounded by lack of analytical specificity of immunoassays. Liquid chromatography tandem mass spectrometry (LC-MS/MS) assays would help overcome these issues. Ionised calcium measurement is recommended for assessment of serum calcium, especially in CKD. Fibroblast growth factor 23 (FGF23) is important in the homeostasis of phosphate that accumulates in CKD, though this marker is not yet utilized in clinical context. Calculated maximal tubular reabsorption of phosphate normalized to glomerular filtration rate (TmP/GFR) may help in assessment of phosphate homeostasis. Bone specific alkaline phosphatase (BALP) and tartrate-resistant acid phosphatase isoform 5b (TRACP5b), the reference markers of bone formation and resorption for CKD-associated osteoporosis, have been shown to reflect bone turnover by histomorphometry in patients with advanced CKD.
- Open Access
- 15 March 2024
- Published by Czech Chemical Society in Chemické listy
- Vol. 118 (3) , 138-145
Tau Protein in Biological Fluids and Its Clinical Value
The tau protein is one of the neurocytoskeletal proteins that participate in the pathogenesis of serious neurological diseases, especially Alzheimer's disease. The tau protein is characterized by considerable structural variability, which is reflected in the existence of its numerous proteoforms. This review aims to provide brief information on the structure of tau protein and its proteoforms, which seem promising biomarkers for clinical use. Biological fluids, suitable for laboratory examination in clinical practice, i.e., cerebrospinal fluid and blood (plasma/serum), are discussed. Total tau protein and its phosphorylated forms (mainly the pT181-tau protein, phosphorylated at the threonine residue 181) have already found clinical application in diagnosis of Alzheimer's disease.
- 15 March 2024
- Published by Czech Chemical Society in Chemické listy
- Vol. 118 (3) , 138-145
Open AccessTau Protein in Biological Fluids and Its Clinical Value
The tau protein is one of the neurocytoskeletal proteins that participate in the pathogenesis of serious neurological diseases, especially Alzheimer's disease. The tau protein is characterized by considerable structural variability, which is reflected in the existence of its numerous proteoforms. This review aims to provide brief information on the structure of tau protein and its proteoforms, which seem promising biomarkers for clinical use. Biological fluids, suitable for laboratory examination in clinical practice, i.e., cerebrospinal fluid and blood (plasma/serum), are discussed. Total tau protein and its phosphorylated forms (mainly the pT181-tau protein, phosphorylated at the threonine residue 181) have already found clinical application in diagnosis of Alzheimer's disease.
- 26 January 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (4) , 257-266
Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas
- 26 January 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (4) , 257-266
Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas
- Open Access
- 15 August 2023
- Published by American Association for Cancer Research (AACR)
Figure 4 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Results of KAP1 and CHK2 kinase assays for 430 successfully analyzed missense CHEK2 variants (shown as an average relative CHK2 kinase activity). Bars are colored as functionally WT-like (green), intermediate (IM; yellow), and impaired (ID; red), respectively, with thresholds for IM variants (0.428 and 0.479) and ID variants (0.705 and 0.710) for KAP1 and CHK2 assays, respectively (dashed lines). Error bars represent standard errors of mean. Color/gray letters for protein variants indicate concordant/discordant functional assays result, respectively. Blue boxes denote conserved CHK2 domains. DNL, variants that do not localize into the nucleus.
- 15 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
Results of KAP1 and CHK2 kinase assays for 430 successfully analyzed missense CHEK2 variants (shown as an average relative CHK2 kinase activity). Bars are colored as functionally WT-like (green), intermediate (IM; yellow), and impaired (ID; red), respectively, with thresholds for IM variants (0.428 and 0.479) and ID variants (0.705 and 0.710) for KAP1 and CHK2 assays, respectively (dashed lines). Error bars represent standard errors of mean. Color/gray letters for protein variants indicate concordant/discordant functional assays result, respectively. Blue boxes denote conserved CHK2 domains. DNL, variants that do not localize into the nucleus.